---
document_datetime: 2025-12-29 13:02:00
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/temybric-ellipta.html
document_name: temybric-ellipta.html
version: success
processing_time: 0.0948597
conversion_datetime: 2025-12-31 03:46:17.510159
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Temybric Ellipta

[RSS](/en/individual-human-medicine.xml/67217)

##### Lapsed

This medicine's authorisation has lapsed

fluticasone furoate / umeclidinium / vilanterol Medicine Human Lapsed

On Monday, 12 January 2026, between 07:00 and 10:00 CET (Amsterdam time), this website will be unavailable due to scheduled maintenance.

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Temybric Ellipta](#news-on)
- [More information on Temybric Ellipta](#related-medicines)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

On 14 June 2022, the marketing authorisation of Temybric Ellipta (fluticasone furoate / umeclidinium / vilanterol) ceased to be valid in the European Union (EU). The cessation of validity is due to the fact that the marketing authorisation holder, GlaxoSmithKline Trading Services Limited, had not marketed Temybric Ellipta in the EU since its initial marketing authorisation.

In accordance with provisions of the sunset clause, the marketing authorisation of the medicinal product lapsed as the product had not been marketed in any of the EU Member States within three years of its initial authorisation. GlaxoSmithKline Trading Services Limited confirmed that the product had not been marketed due to commercial reasons.

Temybric Ellipta was granted marketing authorisation in the EU on 12 June 2019 for treatment of adult patients with chronic obstructive pulmonary disease (COPD). The marketing authorisation was initially valid for a 5-year period. Temybric Ellipta was a duplicate application to Trelegy Ellipta, which is marketed in several EU countries. The marketing authorisation holder will maintain the marketing authorisation for Trelegy Ellipta and its other duplicate Elebrato Ellipta.

The European Public Assessment Report (EPAR) for Temybric Ellipta is updated to indicate that the marketing authorisation is no longer valid.

Temybric Ellipta : EPAR - Medicine overview

Reference Number: EMA/247773/2019

English (EN) (224.86 KB - PDF)

**First published:** 23/09/2019

**Last updated:** 24/11/2022

[View](/en/documents/overview/temybric-ellipta-epar-medicine-overview_en.pdf)

Temybric Ellipta : EPAR - Risk-management-plan summary

English (EN) (561.72 KB - PDF)

**First published:** 23/09/2019

**Last updated:** 24/11/2022

[View](/en/documents/rmp-summary/temybric-ellipta-epar-risk-management-plan-summary_en.pdf)

## Product information

Temybric Ellipta : EPAR - Product Information

English (EN) (1.15 MB - PDF)

**First published:** 23/09/2019

**Last updated:** 24/11/2022

[View](/en/documents/product-information/temybric-ellipta-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-63)

български (BG) (1.82 MB - PDF)

**First published:**

23/09/2019

**Last updated:**

24/11/2022

[View](/bg/documents/product-information/temybric-ellipta-epar-product-information_bg.pdf)

español (ES) (1.22 MB - PDF)

**First published:**

23/09/2019

**Last updated:**

24/11/2022

[View](/es/documents/product-information/temybric-ellipta-epar-product-information_es.pdf)

čeština (CS) (1.64 MB - PDF)

**First published:**

23/09/2019

**Last updated:**

24/11/2022

[View](/cs/documents/product-information/temybric-ellipta-epar-product-information_cs.pdf)

dansk (DA) (1.13 MB - PDF)

**First published:**

23/09/2019

**Last updated:**

24/11/2022

[View](/da/documents/product-information/temybric-ellipta-epar-product-information_da.pdf)

Deutsch (DE) (1.21 MB - PDF)

**First published:**

23/09/2019

**Last updated:**

24/11/2022

[View](/de/documents/product-information/temybric-ellipta-epar-product-information_de.pdf)

eesti keel (ET) (1.15 MB - PDF)

**First published:**

23/09/2019

**Last updated:**

24/11/2022

[View](/et/documents/product-information/temybric-ellipta-epar-product-information_et.pdf)

ελληνικά (EL) (1.93 MB - PDF)

**First published:**

23/09/2019

**Last updated:**

24/11/2022

[View](/el/documents/product-information/temybric-ellipta-epar-product-information_el.pdf)

français (FR) (1.28 MB - PDF)

**First published:**

23/09/2019

**Last updated:**

24/11/2022

[View](/fr/documents/product-information/temybric-ellipta-epar-product-information_fr.pdf)

hrvatski (HR) (1.25 MB - PDF)

**First published:**

23/09/2019

**Last updated:**

24/11/2022

[View](/hr/documents/product-information/temybric-ellipta-epar-product-information_hr.pdf)

íslenska (IS) (1.35 MB - PDF)

**First published:**

23/09/2019

**Last updated:**

24/11/2022

[View](/is/documents/product-information/temybric-ellipta-epar-product-information_is.pdf)

italiano (IT) (1.21 MB - PDF)

**First published:**

23/09/2019

**Last updated:**

24/11/2022

[View](/it/documents/product-information/temybric-ellipta-epar-product-information_it.pdf)

latviešu valoda (LV) (1.58 MB - PDF)

**First published:**

23/09/2019

**Last updated:**

24/11/2022

[View](/lv/documents/product-information/temybric-ellipta-epar-product-information_lv.pdf)

lietuvių kalba (LT) (1.28 MB - PDF)

**First published:**

23/09/2019

**Last updated:**

24/11/2022

[View](/lt/documents/product-information/temybric-ellipta-epar-product-information_lt.pdf)

magyar (HU) (1.73 MB - PDF)

**First published:**

23/09/2019

**Last updated:**

24/11/2022

[View](/hu/documents/product-information/temybric-ellipta-epar-product-information_hu.pdf)

Malti (MT) (1.6 MB - PDF)

**First published:**

23/09/2019

**Last updated:**

24/11/2022

[View](/mt/documents/product-information/temybric-ellipta-epar-product-information_mt.pdf)

Nederlands (NL) (1.2 MB - PDF)

**First published:**

23/09/2019

**Last updated:**

24/11/2022

[View](/nl/documents/product-information/temybric-ellipta-epar-product-information_nl.pdf)

norsk (NO) (1.31 MB - PDF)

**First published:**

23/09/2019

**Last updated:**

24/11/2022

[View](/no/documents/product-information/temybric-ellipta-epar-product-information_no.pdf)

polski (PL) (1.59 MB - PDF)

**First published:**

23/09/2019

**Last updated:**

24/11/2022

[View](/pl/documents/product-information/temybric-ellipta-epar-product-information_pl.pdf)

português (PT) (1.43 MB - PDF)

**First published:**

23/09/2019

**Last updated:**

24/11/2022

[View](/pt/documents/product-information/temybric-ellipta-epar-product-information_pt.pdf)

română (RO) (1.44 MB - PDF)

**First published:**

23/09/2019

**Last updated:**

24/11/2022

[View](/ro/documents/product-information/temybric-ellipta-epar-product-information_ro.pdf)

slovenčina (SK) (1.6 MB - PDF)

**First published:**

23/09/2019

**Last updated:**

24/11/2022

[View](/sk/documents/product-information/temybric-ellipta-epar-product-information_sk.pdf)

slovenščina (SL) (1.82 MB - PDF)

**First published:**

23/09/2019

**Last updated:**

24/11/2022

[View](/sl/documents/product-information/temybric-ellipta-epar-product-information_sl.pdf)

Suomi (FI) (1.2 MB - PDF)

**First published:**

23/09/2019

**Last updated:**

24/11/2022

[View](/fi/documents/product-information/temybric-ellipta-epar-product-information_fi.pdf)

svenska (SV) (1.15 MB - PDF)

**First published:**

23/09/2019

**Last updated:**

24/11/2022

[View](/sv/documents/product-information/temybric-ellipta-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** WS/2130/G 11/12/2021

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Temybric Ellipta : EPAR - All Authorised presentations

English (EN) (167.41 KB - PDF)

**First published:** 23/09/2019

**Last updated:** 24/11/2022

[View](/en/documents/all-authorised-presentations/temybric-ellipta-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-448)

български (BG) (214.29 KB - PDF)

**First published:**

23/09/2019

**Last updated:**

24/11/2022

[View](/bg/documents/all-authorised-presentations/temybric-ellipta-epar-all-authorised-presentations_bg.pdf)

español (ES) (165.63 KB - PDF)

**First published:**

23/09/2019

**Last updated:**

24/11/2022

[View](/es/documents/all-authorised-presentations/temybric-ellipta-epar-all-authorised-presentations_es.pdf)

čeština (CS) (191.16 KB - PDF)

**First published:**

23/09/2019

**Last updated:**

24/11/2022

[View](/cs/documents/all-authorised-presentations/temybric-ellipta-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (169.96 KB - PDF)

**First published:**

23/09/2019

**Last updated:**

24/11/2022

[View](/da/documents/all-authorised-presentations/temybric-ellipta-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (160.11 KB - PDF)

**First published:**

23/09/2019

**Last updated:**

24/11/2022

[View](/de/documents/all-authorised-presentations/temybric-ellipta-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (198.72 KB - PDF)

**First published:**

23/09/2019

**Last updated:**

24/11/2022

[View](/et/documents/all-authorised-presentations/temybric-ellipta-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (196.94 KB - PDF)

**First published:**

23/09/2019

**Last updated:**

24/11/2022

[View](/el/documents/all-authorised-presentations/temybric-ellipta-epar-all-authorised-presentations_el.pdf)

français (FR) (170.07 KB - PDF)

**First published:**

23/09/2019

**Last updated:**

24/11/2022

[View](/fr/documents/all-authorised-presentations/temybric-ellipta-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (172.77 KB - PDF)

**First published:**

23/09/2019

**Last updated:**

24/11/2022

[View](/hr/documents/all-authorised-presentations/temybric-ellipta-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (242.14 KB - PDF)

**First published:**

23/09/2019

**Last updated:**

24/11/2022

[View](/is/documents/all-authorised-presentations/temybric-ellipta-epar-all-authorised-presentations_is.pdf)

italiano (IT) (191.29 KB - PDF)

**First published:**

23/09/2019

**Last updated:**

24/11/2022

[View](/it/documents/all-authorised-presentations/temybric-ellipta-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (191.53 KB - PDF)

**First published:**

23/09/2019

**Last updated:**

24/11/2022

[View](/lv/documents/all-authorised-presentations/temybric-ellipta-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (286.73 KB - PDF)

**First published:**

23/09/2019

**Last updated:**

24/11/2022

[View](/lt/documents/all-authorised-presentations/temybric-ellipta-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (184.55 KB - PDF)

**First published:**

23/09/2019

**Last updated:**

24/11/2022

[View](/hu/documents/all-authorised-presentations/temybric-ellipta-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (191.18 KB - PDF)

**First published:**

23/09/2019

**Last updated:**

24/11/2022

[View](/mt/documents/all-authorised-presentations/temybric-ellipta-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (166.79 KB - PDF)

**First published:**

23/09/2019

**Last updated:**

24/11/2022

[View](/nl/documents/all-authorised-presentations/temybric-ellipta-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (167.85 KB - PDF)

**First published:**

23/09/2019

**Last updated:**

24/11/2022

[View](/no/documents/all-authorised-presentations/temybric-ellipta-epar-all-authorised-presentations_no.pdf)

polski (PL) (250.1 KB - PDF)

**First published:**

23/09/2019

**Last updated:**

24/11/2022

[View](/pl/documents/all-authorised-presentations/temybric-ellipta-epar-all-authorised-presentations_pl.pdf)

português (PT) (205.67 KB - PDF)

**First published:**

23/09/2019

**Last updated:**

24/11/2022

[View](/pt/documents/all-authorised-presentations/temybric-ellipta-epar-all-authorised-presentations_pt.pdf)

română (RO) (185.83 KB - PDF)

**First published:**

23/09/2019

**Last updated:**

24/11/2022

[View](/ro/documents/all-authorised-presentations/temybric-ellipta-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (190.45 KB - PDF)

**First published:**

23/09/2019

**Last updated:**

24/11/2022

[View](/sk/documents/all-authorised-presentations/temybric-ellipta-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (181.59 KB - PDF)

**First published:**

23/09/2019

**Last updated:**

24/11/2022

[View](/sl/documents/all-authorised-presentations/temybric-ellipta-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (159.86 KB - PDF)

**First published:**

23/09/2019

**Last updated:**

24/11/2022

[View](/fi/documents/all-authorised-presentations/temybric-ellipta-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (165.14 KB - PDF)

**First published:**

23/09/2019

**Last updated:**

24/11/2022

[View](/sv/documents/all-authorised-presentations/temybric-ellipta-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Temybric Ellipta Active substance

- fluticasone furoate
- umeclidinium bromide
- vilanterol trifenatate

International non-proprietary name (INN) or common name

- fluticasone furoate
- umeclidinium
- vilanterol

Therapeutic area (MeSH) Pulmonary Disease, Chronic Obstructive Anatomical therapeutic chemical (ATC) code R03AL08

### Pharmacotherapeutic group

Drugs for obstructive airway diseases

### Therapeutic indication

Temybric Ellipta is indicated as a maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting ?2-agonist or a combination of a long-acting ?2-agonist and a long-acting muscarinic antagonist (for effects on symptom control and prevention of exacerbations see section 5.1).

## Authorisation details

EMA product number EMEA/H/C/005254 Marketing authorisation holder

GlaxoSmithKline Trading Services Limited

12 Riverwalk Citywest Business Campus Dublin 24 D24 YK11 Ireland

Marketing authorisation issued 12/06/2019 Lapse of marketing authorisation 14/06/2022 Revision 4

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Temybric Ellipta : EPAR - Procedural steps taken and scientific information after the authorisation

English (EN) (304.11 KB - PDF)

**First published:** 12/02/2020

**Last updated:** 24/11/2022

[View](/en/documents/procedural-steps-after/temybric-ellipta-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf)

Questions and answers on the refusal of a change to the marketing authorisation for Temybric Ellipta (fluticasone furoate / umeclidinium / vilanterol)

Adopted

Reference Number: EMA/126142/2021

English (EN) (244.75 KB - PDF)

**First published:** 26/02/2021

**Last updated:** 24/11/2022

[View](/en/documents/smop/questions-and-answers-refusal-change-marketing-authorisation-temybric-ellipta-fluticasone-furoate-umeclidinium-vilanterol_en.pdf)

## Initial marketing authorisation documents

Temybric Ellipta : EPAR - Public assessment report

Adopted

Reference Number: EMA/299628/2019

English (EN) (339.31 KB - PDF)

**First published:** 23/09/2019

**Last updated:** 24/11/2022

[View](/en/documents/assessment-report/temybric-ellipta-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Temybric Ellipta

Adopted

Reference Number: EMA/CHMP/228757/2019

English (EN) (222.16 KB - PDF)

**First published:** 26/04/2019

**Last updated:** 24/11/2022

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-temybric-ellipta_en.pdf)

#### News on Temybric Ellipta

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 February 2021](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-february-2021) 26/02/2021

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 23-26 April 2019](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-23-26-april-2019) 26/04/2019

#### More information on Temybric Ellipta

- [EMEA-002153-PIP01-17-M01 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-002153-pip01-17-m01)

**This page was last updated on** 24/11/2022

## Share this page

[Back to top](#main-content)